|Articles|March 15, 2004
EC approves bimatoprost as first-line therapy
London-The European Commission (EC) has approved Allergan Inc.'s bimatoprost ophthalmic solution 0.03% (Lumigan) as a first-line therapy to reduce IOP in chronic open-angle glaucoma and ocular hypertension.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
























